PharmaCyte Biotech, Inc. 10-Q

Item 5. Other Information . None. 34 Item 6. Exhibits. Exhibit No. Description Location 10.1 Right of First Refusal Agreement by and between PharmaCyte Biotech, Inc. and Silver Rock Associates, Inc., dated May 4, 2020 Filed herewith 10.2 Amendment No. 1 to Right of First Refusal Agreement by and between PharmaCyte Biotech, Inc. and Silver Rock Associates, Inc., dated July 15, 2020 Filed herewith 31.1 Principal Executive Officer Certification required by Rules 13a-14 and 15d-14 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Filed herewith 31.2 Principal Financial Officer Certification required by Rules 13a-14 and 15d-14 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Filed herewith 32.1 Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of Sarbanes Oxley Act of 2002. Filed herewith 32.2 Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of Sarbanes Oxley Act of 2002. Filed herewith 101. Interactive Data Files for the Company’s Form 10-Q for the period ended July 31, 2020 Submitted herewith. 35 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized. PharmaCyte Biotech, Inc. September 11, 2020 By: /s/ Kenneth L. Waggoner Kenneth L. Waggoner Chief Executive Officer (Duly Authorized Officer and Principal Executive Officer) September 11, 2020 By: /s/ Carlos A. Trujillo Carlos A. Trujillo Chief Financial Officer (Duly Authorized Officer and Principal Financial and Principal Accounting Officer) 36